Építés alatt – nem éles oldal
Belépés
Résztvevőt keresFázis nélkül

Remibrutinib in Real-world Clinical Practice - a Germany Sub-study (REASSERT)

A legfontosabb adatok

Ki végzi
Novartis Pharmaceuticals
Hol
Németország1 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Toboroz
Résztvevők
470 fő, tervezett
Kezdés
2026. aug. 4.
Várható befejezés
2029. máj. 31.
A vizsgálat típusa
Megfigyeléses, 2 csoport
A regiszteradat frissítve
2026. augusztus 7.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for adults with chronic spontaneous urticaria (CSU, long-lasting hives with no known trigger). Their doctor must already have decided to switch them to remibrutinib.

Életkor
18 years and older
Nem
All sexes
A betegség stádiuma
Primary CSU confirmed by the treating doctor. Cohort 2: CSU not well controlled despite licensed or increased doses of sgH1-AH (second-generation antihistamines).
Korábbi kezelés
Cohort 2: only sgH1-AH before, with first generation H1-AH also allowed. Cohort 3: any other treatment in addition to H1-AH at any time, including continuous steroids for at least 3 weeks. Occasional steroid rescue medicine does not decide the cohort. People who ever had remibrutinib cannot join.

A részvétel fő kizáró okai

  • Taking part in any investigational trial, or in another Novartis-sponsored non-interventional study with remibrutinib
  • Being in the safety follow-up phase of an earlier study
  • Having had remibrutinib at any time before
  • Not able or willing to enter diary data electronically for the whole study
  • Getting remibrutinib outside of the local label

A regiszter feltételei, szó szerint

Mind a 11 feltétel megnézéseKevesebb

Ki vehet részt

  • 7.2.1 Inclusion criteria Patients must meet all the following criteria to be eligible for inclusion in this study
  • Patients with a confirmed diagnosis of primary CSU by the treating physician
  • Aged at least 18 years on the date of enrollment
  • Written informed consent of the patient to participate in the study and willingness to complete full follow-up period of 24 months
  • Cohort-specific observational inclusion criteria:; Cohort 2: Inadequate control of CSU despite licensed dose or escalated sgH1-AH(s) (no other pre-treatment with exception of first generation H1-AH permitted) with decision (independent of study enrollment) to switch to remibrutinib treatment as per local label; Cohort3: Any other treatment received in addition to H1-AH, any time during patients' CSU treatment history, with decision (independent of study enrollment) to switch to remibrutinib treatment as per local label. Note, occasional steroid rescue medication is out of scope for cohort definition. If a patient had been on continuous steroids for at least 3 weeks during treatment history, they will be included in cohort 3

Ki nem vehet részt

  • Patients within the safety follow-up phase of a previous interventional or non-interventional study
  • Patients who received remibrutinib at any time in the past
  • Patients who are treated with remibrutinib outside of the local label
  • Patients are excluded if they meet any of the following criteria:
  • Simultaneous participation in any investigational trial or simultaneous participation in another Novartis-sponsored non-interventional study with remibrutinib
  • Patients not capable or willing to continuously provide ePRO/eDiary data via electronic means throughout the duration of the study

Ez a vizsgálat jelenleg itt érhető el: Németország.

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

Prospective, non-interventional study in patients with CSU where the treatment decision prior enrolment has been made to escalate/switch current treatment to remibrutinib. The primary aim of this study is to gather real-world effectiveness and safety data for remibrutinib, a new treatment option, covering a broader, real-world clinical practice population.

A vizsgálat 2 csoportja

  • Cohort 2

    Inadequate control of CSU despite licensed dose or escalated sgH1-AH(s) (no other pre-treatment with exception of first generation H1-AH permitted) with decision (independent of study enrollment) to switch to remibrutinib treatment as per local label. Baseline visit comprises of clinical assessment while treated with sgH1-AH (i.e., preescalation to remibrutinib) and follow-up visits capture clinical outcome of escalated treatment with remibrutinib as per local label.

  • Cohort 3

    Any other treatment received in addition to H1-AH, any time during patients CSU treatment history, with decision (independent of study enrollment) to switch to remibrutinib treatment as per local label. Baseline visit comprises of clinical assessment before switch to remibrutinib and follow-up visits capture clinical outcome of treatment with remibrutinib as per local label. Enrollment will be capped at a maximum of 30% of the local population.

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Remibrutinib in Real-world Clinical Practice: a Prospective, Multi-country, Non-interventional, Effectiveness and Safety Study (REASSERT) - Local Adaptation in Germany From Global Umbrella Protocol (CLOU064A2402)
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 15.
A regiszteradat frissítve
2026. augusztus 7.